WHO Drug Information Vol 23, No. 3, 2009                                                  Recommended INN: List 62



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 62
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in Cumulative List
No. 12, 2007 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 62
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans
la Liste récapitulative No. 12, 2007 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 62
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente
anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes
Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes
Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en
farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran
reunidas en Cumulative List No. 12, 2007 (disponible sólo en CD-ROM).

                                                                                                                   237
Recommended INN: List 62                                                  WHO Drug Information Vol 23, No. 3, 2009




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada


 adarotenum
 adarotene                                 (2E)-3-[3'-(adamantan-1-yl)-4'-hydroxy-1,1'-biphenyl-4-yl]prop-
                                           2-enoic acid

 adarotène                                 acide (2E)-3-[4'-hydroxy-3'-(adamantan-1-yl)biphényl-4-yl]prop-
                                           2-énoïque

 adaroteno                                 ácido 3-[3'-(adamantan-1-il)-4'-hidroxi-1,1'-bifenil-4-il]prop-2-enoico

                                           C25H26O3

                                                  HO




                                                                                CO2H




 afamelanotidum
 afamelanotide                             N-acetyl-L-serinyl-L-tyrosyl-L-seryl-(2S)-2-aminohexanoyl-L-glutamyl-
                                           L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophanylglycyl-L-lysyl-
                                           L-prolyl-L-valinamide

 afamélanotide                             N-acétyl-L-sérinyl-L-tyrosyl-L-séryl-(2S)-2-aminohexanoyl-L-glutamyl-
                                           L-histidyl-D-phénylalanyl-L-arginyl-L-tryptophanylglycyl-L-lysyl-
                                           L-prolyl-L-valinamide

 afamelanotida                             N-acetil-L-serinil-L-tirosil-L-seril-(2S)-2-aminohexanoil-L-glutamil-
                                           L-histidil-D-fenilalanil-L-arginil-L-triptofanilglicil-L-lisil-L-prolil-
                                           L-valinamida

                                           C78H111N21O19

                                                         H3C
                                                                      H
                                            H3C
                                                      Ser Tyr Ser N       Glu His D-Phe Arg Trp Gly Lys Pro Val NH2
                                                                  H
                                                  O                   O




 alisporivirum
 alisporivir                               [8-(N-methyl-D-alanine),9-(N-ethyl-L-valine)]cyclosporine

 alisporivir                               [8-(N-méthyl-D-alanine),9-(N-éthyl-L-valine)]cyclosporine

 alisporivir                               [8-(N-metil-D-alanina),9-(N-etil-L-valina)]ciclosporina




238
WHO Drug Information Vol 23, No. 3, 2009                                                                      Recommended INN: List 62


                                           C63H113N11O12

                                                                                                                    CH3
                                                               CH3                         H3 C
                                                                                   CH3     H                       CH3
                                                                                                          OH
                                                       H3C               H3C        H         H                     H
                                                               H                                          H                    CH3
                                                       H3 C                                                                       H
                                                               N               N            N                 N               N
                                                                                                              H                       CH3
                                                                         O CH3         O CH3          O                  O
                                           H3 C                      O                                            H3 C                O
                                                       H             CH3                                                       N
                                                                                                                                     H
                                              H3C              N               O            O     H3C O                                   CH3
                                                                         H             H                                 H
                                                                         N             N              N                  N
                                                           O
                                                                                                                                   O CH3
                                                               H3C       H     H CH3 H                        H              CH3
                                                                                  H3C                         H3 C
                                                                                                  CH3


 amenamevirum
 amenamevir                                N-(2,6-dimethylphenyl)-N-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl]amino}-
                                           2-oxoethyl)-1,1-dioxothiane-4-carboxamide

 aménamévir                                N-(2,6-diméthylphényl)-N-(2-{[4-(1,2,4-oxadiazol-3-yl)phényl]amino}-
                                           2-oxoéthyl)-1,1-dioxothiane-4-carboxamide

 amenamevir                                N-(2,6-dimetilfenil)-N-(2-{[4-(1,2,4-oxadiazol-3-il)fenil]amino}-
                                           2-oxoetil)-1,1-dioxotiano-4-carboxamida

                                           C24H26N4O5S



                                                                                                  N
                                             O      H3C                      CH3                              O
                                           O S                               O                            N

                                                                   N
                                                                                   N
                                                                                   H
                                                               O


 atigliflozinum
 atigliflozin                              2-[(4-methoxyphenyl)methyl]thiophen-3-yl β-D-glucopyranoside

 atigliflozine                             β-D-glucopyranoside de 2-[(4-méthoxyphényl)méthyl]thiophén-3-yle

 atigliflozina                             β-D-glucopiranósido de 2-[(4-metoxifenil)metil]-3-tienilo

                                           C18H22O7S

                                                                   OCH3




                                           HO                            S

                                                        O O
                                                  OH
                                           HO
                                                        OH


                                                                                                                                                239
Recommended INN: List 62                                       WHO Drug Information Vol 23, No. 3, 2009


 balapiravirum
 balapiravir               4'-C-azido-2',3',5'-tris[O-(2-methylpropanoyl)]cytidine

 balapiravir               4'-C-azido-2',3',5'-tris[O-(2-méthylpropanoyl)]cytidine

 balapiravir               4'-C-azido-2',3',5'-tris[O-(2-metilpropanoil)]citidina

                           C21H30N6O8

                                                         NH2
                                 CH3
                                        O            N
                           H3C
                                    O            O       N
                                                 O


                                        N3                   CH3
                                    O        O       O
                                                                 CH3
                                                         O
                                  H3C        CH3



 beloranibum
 beloranib                 (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-
                           2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl (2E)-3-{4-[2-
                           (dimethylamino)ethoxy]phenyl}prop-2-enoate

 béloranib                 (2E)-3-{4-[2-(diméthylamino)éthoxy]phényl}prop-2-énoate de
                           (3R,4S,5S,6R)-5-méthoxy-4-[(2R,3R)-2-méthyl-3-(3-méthylbut-2-én-
                           1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yle

 beloranib                 (2E)-3-{4-[2-(dimetilamino)etoxi]fenil}prop-2-enoato de
                           (3R,4S,5S,6R)- 4-[(2R,3R)-2-metil-3-(3-metilbut-2-en-1-il)oxiran-2-il]-
                           5-metoxi-1-oxaspiro[2.5]octan-6-ilo

                           C29H41NO6

                                                                                    O           CH3
                                                 CH3 H OCH3                                 N
                                             O
                                                          O                                 CH3
                           H3C
                                                 H               H
                                             H                       O
                                 CH3
                                                     O



 blinatumomabum #
 blinatumomab              immunoglobulin scFv-scFv, anti-[Homo sapiens CD19 (B lymphocyte
                           surface antigen B4, Leu-12)]/anti-[Homo sapiens CD3 epsilon
                           (CD3E, Leu-4)] Mus musculus monoclonal antibody bispecific single
                           chain;
                           Mus musculus scFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01)
                           [10.3.9] (1-111) -tris(tetraglycyl-seryl) -VH (IGHV1-54-(IGHD)-
                           IGHJ4*01, S123>T) [8.8.17] (127-250)] -tetraglycyl-seryl -Mus
                           musculus scFv anti-CD3E [VH (IGHV1-4-(IGHD)-IGHJ2*01) [8.8.12]
                           (256-374) -valyl-glutamyl-tetrakis(diglycyl-seryl)-diglycyl-valyl-
                           aspartyl -V-KAPPA (IGKV4-59-IGKJ5*01) [5.3.9] (393-498)] -
                           hexahistidine




240
WHO Drug Information Vol 23, No. 3, 2009                                                             Recommended INN: List 62


 blinatumomab                              immunoglobuline scFv-scFv, anti-[Homo sapiens CD19 (antigène de
                                           surface B4 des lymphocytes B, Leu-12)]/anti-[Homo sapiens CD3
                                           epsilon (CD3E, Leu-4)] Mus musculus anticorps monoclonal
                                           bispécifique à chaîne unique;
                                           Mus musculus scFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01)
                                           [10.3.9] (1-111) -tris(tétraglycyl-séryl) -VH (IGHV1-54-(IGHD)-
                                           IGHJ4*01, S123>T [8.8.17] (127-250) -tétraglycyl-séryl -Mus
                                           musculus scFv anti-CD3E [VH (IGHV1-4-(IGHD)-IGHJ2*01 [8.8.12]
                                           (256-374) -valyl-glutamyl-tétrakis(diglycyl-seryl)-diglycyl-valyl-
                                           aspartyl -V-KAPPA (IGKV4-59-IGKJ5*01 [5.3.9] (393-498)] –
                                           hexahistidine

 blinatumomab                              inmunoglobulina scFv-scFv, anti-[Homo sapiens CD19 (antígeno de
                                           superficie B4 de los linfocitos B, Leu-12)]/anti-[Homo sapiens CD3
                                           epsilon (CD3E, Leu-4)] anticuerpo monoclonal biespecífico de Mus
                                           musculus de cadena única;
                                           Mus musculus scFv anti-CD19 [V-KAPPA (IGKV3-4-IGKJ1*01)
                                           [10.3.9] (1-111) -tris(tetraglicil-seril) -VH (IGHV1-54-(IGHD)-
                                           IGHJ4*01, S123>T [8.8.17] (127-250) -tetraglicil-seril -Mus musculus
                                           scFv anti-CD3E [VH (IGHV1-4-(IGHD)-IGHJ2*01 [8.8.12] (256-374) -
                                           valil-glutamil-tetrakis(diglicil-seril)-diglicil-valil-aspartil -V-KAPPA
                                           (IGKV4-59-IGKJ5*01 [5.3.9] (393-498)] –hexahistidina

                                           C2367H3577N649O772S19

                                           DIQLTQSPAS       LAVSLGQRAT      ISCKASQSVD       YDGDSYLNWY         QQIPGQPPKL         50
                                           LIYDASNLVS       GIPPRFSGSG      SGTDFTLNIH       PVEKVDAATY         HCQQSTEDPW        100
                                           TFGGGTKLEI       KGGGGSGGGG      SGGGGSQVQL       QQSGAELVRP         GSSVKISCKA        150
                                           SGYAFSSYWM       NWVKQRPGQG      LEWIGQIWPG       DGDTNYNGKF         KGKATLTADE        200
                                           SSSTAYMQLS       SLASEDSAVY      FCARRETTTV       GRYYYAMDYW         GQGTTVTVSS        250
                                           GGGGSDIKLQ       QSGAELARPG      ASVKMSCKTS       GYTFTRYTMH         WVKQRPGQGL        300
                                           EWIGYINPSR       GYTNYNQKFK      DKATLTTDKS       SSTAYMQLSS         LTSEDSAVYY        350
                                           CARYYDDHYC       LDYWGQGTTL      TVSSVEGGSG       GSGGSGGSGG         VDDIQLTQSP        400
                                           AIMSASPGEK       VTMTCRASSS      VSYMNWYQQK       SGTSPKRWIY         DTSKVASGVP        450
                                           YRFSGSGSGT       SYSLTISSME      AEDAATYYCQ       QWSSNPLTFG         AGTKLELKHH        500
                                           HHHH                                                                                   504

                                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                           23-92 148-222 277-351 415-479

                                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                           307 (but Pro in 308)


 canosimibum
 canosimibe                                N-(1-deoxy-D-glucitol-1-C-yl)-N'-[(4-{(2S,3R))-3-[(3S)-3-(4-
                                           fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-
                                           1-yl}phenyl)methyl]dodecanediamide

 canosimibe                                N-(1-déoxy-D-glucitol-1-C-yl)-N'-[(4-{(2S,3R))-3-[(3S)-3-(4-
                                           fluorophényl)-3-hydroxypropyl]-2-(4-méthoxyphényl)-4-oxoazétidin-
                                           1-yl}phényl)méthyl]dodécanediamide

 canosimiba                                N-(1-desoxi-D-glucitol-1-C-il)-N'-[(4-{(2S,3R))-3-[(3S)-3-(4-
                                           fluorofenil)-3-hidroxipropil]-2-(4-metoxifenil)-4-oxoazetidin-
                                           1-il}fenil)metil]dodecanediamida

                                           C44H60FN3O10

                                                                                                                OH       OH
                                                        H   OH               O                              H                 H
                                                                      H                               HO
                                                                                                                                    NH
                                                                                                                         H      H
                                                                            N                                       OH       OH
                                           F                                                                                   O
                                                                       H                        H
                                                                                                N
                                                  H3CO
                                                                                                    O



                                                                                                                                         241
Recommended INN: List 62                                      WHO Drug Information Vol 23, No. 3, 2009




 cixutumumabum #
 cixutumumab               immunoglobulin G1-lambda, anti-[Homo sapiens insulin-like growth
                           factor I receptor (IGF-1R, CD221)], Homo sapiens monoclonal
                           antibody;
                           gamma1 heavy chain (1-460) [Homo sapiens VH (IGHV1-69*06
                           (99.00%) -(IGHD)-IGHJ6*01) [8.8.23] (1-130) -IGHG1*03, R120>K
                           (131-460)], (233-213')-disulfide with lambda light chain (1'-214')
                           [Homo sapiens V-LAMBDA (IGLV3-19*01 (92.70%) -IGLJ2*01)
                           [6.3.11] (1'-108') -IGLC2*01, T124>A (109'-214')]; (239-239'':242-
                           242'')-bisdisulfide dimer

 cixutumumab               immunoglobuline G1-lambda, anti-[Homo sapiens récepteur du
                           facteur de croissance analogue à l'insuline-1 (IGF-1R, CD221)],
                           Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-460) [Homo sapiens VH (IGHV1-69*06
                           (99.00%) -(IGHD)-IGHJ6*01) [8.8.23] (1-130) -IGHG1*03, R120>K
                           (131-460)], (233-213')-disulfure avec la chaîne légère lambda
                           (1'-214') [Homo sapiens V-LAMBDA (IGLV3-19 (92.70%) -IGLJ2*01)
                           [6.3.11] (1'-108') -IGLC2*01, T124>A (109'-214')]; dimère (239-
                           239'':242-242'')-bisdisulfure

 cixutumumab               inmunoglobulina G1-lambda, anti-[receptor del factor de crecimiento
                           insulínico-tipo 1 de Homo sapiens (conocido como: IGF-1R,
                           CD221)], Homo sapiens anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-460) [VH (IGHV1-69*06 (99.00%) -
                           (IGHD)-IGHJ6*01) [8.8.23] (1-130) -IGHG1*03, R120>K (131-460)],
                           (233-213')-disulfuro con la cadena ligera lambda (1'-214') [Homo
                           sapiens V-LAMBDA (IGLV3-19 (92.70%) -IGLJ2*01) [6.3.11]
                           (1'-108') -IGLC2*01, T124>A (109'-214')]; dímero (239-239'':242-
                           242'')-bisdisulfuro

                           C6500H10052N1724O2036S44

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGAE VKKPGSSVKV SCKASGGTFS                  SYAISWVRQA       PGQGLEWMGG        50
                           IIPIFGTANY AQKFQGRVTI TADKSTSTAY                  MELSSLRSED       TAVYYCARAP       100
                           LRFLEWSTQD HYYYYYMDVW GKGTTVTVSS                  ASTKGPSVFP       LAPSSKSTSG       150
                           GTAALGCLVK DYFPEPVTVS WNSGALTSGV                  HTFPAVLQSS       GLYSLSSVVT       200
                           VPSSSLGTQT YICNVNHKPS NTKVDKKVEP                  KSCDKTHTCP       PCPAPELLGG       250
                           PSVFLFPPKP KDTLMISRTP EVTCVVVDVS                  HEDPEVKFNW       YVDGVEVHNA       300
                           KTKPREEQYN STYRVVSVLT VLHQDWLNGK                  EYKCKVSNKA       LPAPIEKTIS       350
                           KAKGQPREPQ VYTLPPSREE MTKNQVSLTC                  LVKGFYPSDI       AVEWESNGQP       400
                           ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW                  QQGNVFSCSV       MHEALHNHYT       450
                           QKSLSLSPGK                                                                          460

                           Light chain / Chaîne légère / Cadena ligera
                           SSELTQDPAV SVALGQTVRI TCQGDSLRSY                  YATWYQQKPG       QAPILVIYGE 50
                           NKRPSGIPDR FSGSSSGNTA SLTITGAQAE                  DEADYYCKSR       DGSGQHLVFG 100
                           GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN                  KATLVCLISD       FYPGAVTVAW 150
                           KADSSPVKAG VETTTPSKQS NNKYAASSYL                  SLTPEQWKSH       RSYSCQVTHE 200
                           GSTVEKTVAP AECS                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 157-213              274-334  380-438
                                    22''-96'' 157''-213'' 274''-334'' 380''-438''
                           Intra-L 22'-87' 136'-195'
                                    22'''-87''' 136'''-195'''
                           Inter-H-L 233-213' 233''-213'''
                           Inter-H-H 239-239'' 242-242''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           310, 310''




242
WHO Drug Information Vol 23, No. 3, 2009                                                            Recommended INN: List 62


 coleneuramidum
 coleneuramide                             5-acetamido-N-(5α-cholestan-3α-yl)-3,5-dideoxy-2-O-methyl-
                                           D-glycero-α-D-galacto-non-2-ulopyranosonamide

 coléneuramide                             5-acétamido-N-(5α-cholestan-3α-yl)-3,5-didéoxy-2-O-méthyl-
                                           D-glycéro-α-D-galacto-non-2-ulopyranosonamide

 coleneuramida                             5-acetamido-N-(5α-colestan-3α-il)-3,5-didesoxi-2-O-metil-D-glicero-
                                           α-D-galacto-non-2-ulopiranosonamida

                                           C39H68N2O8

                                                                                            H3C H
                                                                                            CH3
                                                                                                    H         CH3
                                                                               CH3      H               H3C
                                                                   H
                                                         O         N                H       H
                                                     O
                                                         O             H       H
                                             H3C         NH O
                                                                   CH3
                                           HO
                                                         OH
                                                              OH
                                           HO



 cositecanum
 cositecan                                 (4S)-4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-1,12-dihydro-
                                           14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione

 cositécan                                 (4S)-4-éthyl-4-hydroxy-11-[2-(triméthylsilyl)éthyl]-1,12-dihydro-
                                           14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléine-3,14(4H)-dione

 cositecán                                 (4S)-4-etil-4-hidroxi-11-[2-(trimetilsilil)etil]-1,12-dihidro-
                                           14H-pirano[3',4':6,7]indolizino[1,2-b]quinolina-3,14(4H)-diona

                                           C25H28N2O4Si

                                              H3 C
                                                     CH3                       O
                                           H3C Si
                                                                           N            O

                                                                                             O
                                                                   N               HO       CH3




 cutamesinum
 cutamesine                                1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine

 cutamésine                                1-[2-(3,4-diméthoxyphényl)éthyl]-4-(3-phénylpropyl)pipérazine

 cutamesina                                1-[2-(3,4-dimetoxifenil)etil]-4-(3-fenilpropil)piperazina




                                                                                                                         243
Recommended INN: List 62                                       WHO Drug Information Vol 23, No. 3, 2009


                           C23H32N2O2

                                                 N
                                                           N                    OCH3


                                                                                OCH3




 davunetidum
 davunetide                human activity-dependent neuroprotector (ADNP)-(354-361)-peptide

 davunétide                neuroprotecteur activité-dépendant humain (ADNP)-(354-361)-
                           peptide

 davunetida                neuroprotector humano dependiente de actividad (ADNP)-péptido-
                           (354-361)

                           C36H60N10O12

                           H Asn    Ala    Pro       Val   Ser     Ile   Pro   Gln   OH




 delafloxacinum
 delafloxacin              1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-
                           7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic
                           acid

 délafloxacine             acide 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-
                           7-(3-hydroxyazétidin-1-yl)-4-oxo-1,4-dihydroquinoléine-
                           3-carboxylique

 delafloxacino             ácido 1-(6-amino-3,5-difluoropiridin-2-il)-8-cloro-6-fluoro-
                           7-(3-hidroxiazetidin-1-il)-4-oxo-1,4-dihidroquinolina-3-carboxílico

                           C18H12ClF3N4O4

                                                      F
                                          H 2N

                                                 N
                           HO               Cl                 F
                                    N                 N


                                    F                          CO2H
                                                      O



 dirucotidum
 dirucotide                human myelin basic protein (myelin membrane encephalitogenic
                           protein)-(216-232)-peptide
                           L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-
                           L-histidyl-L-phenylalanyl-L-phenylalanyl-L-lysyl-L-asparaginyl-
                           L-isoleucyl-L-valyl-L-threonyl-L-prolyl-L-arginyl-L-threonine




244
WHO Drug Information Vol 23, No. 3, 2009                                                              Recommended INN: List 62


 dirucotide                                protéine basique de la myéline humaine (protéine
                                           encéphalitogénique de la membrane de la myéline)-(216-232)-
                                           peptide
                                           L-α-aspartyl-L-α-glutamyl-L-asparaginyl-L-prolyl-L-valyl-L-valyl-
                                           L-histidyl-L-phénylalanyl-L-phénylalanyl-L-lysyl-L-asparaginyl-
                                           L-isoleucyl-L-valyl-L-thréonyl-L-prolyl-L-arginyl-L-thréonine

 dirucotida                                proteina básica de la mielina humana (proteina encefalitogénica de
                                           la membrana de mielina)-péptido (216-232)
                                           L-α-aspartil-L-α-glutamil-L-asparaginil-L-prolil-L-valil-L-valil-L-histidil-
                                           L-fenilalanil-L-fenilalanil-L-lisil-L-asparaginil-L-isoleucil-L-valil-L-treonil-
                                           L-prolil-L-arginil-L-treonina

                                           C92H141N25O26

                                           H Asp      Glu   Asn    Pro       Val    Val    His   Phe     Phe

                                                Lys   Asn   Ile   Val       Thr    Pro    Arg    Thr OH
                                                 10                                              17




 dutogliptinum
 dutogliptin                               [(2R)-1-{[(3R)-pyrrolidin-3-ylamino]acetyl}pyrrolidin-2-yl]boronic acid

 dutogliptine                              acide [(2R)-1-{[(3R)-pyrrolidin-3-ylamino]acétyl}pyrrolidin-
                                           2-yl]boronique

 dutogliptina                              àcido [(2R)-1-{[(3R)-pirrolidin-3-ilamino]acetil}pirrolidin-2-il]borónico

                                           C10H20BN3O3

                                                                             OH
                                                              O         H
                                                       H                     B
                                           HN          N                          OH
                                                                  N
                                                       H




 elacytarabinum
 elacytarabine                             4-amino-1-{5-O-[(9E)-octadec-9-enoyl]-β-D-arabinofuranosyl}=
                                           pyrimidin-2(1H)-one

 élacytarabine                             4-amino-1-[5-O-[(9E)-octadéc-9-énoyl]-β-D-arabinofuranosyl]=
                                           pyrimidin-2(1H)-one

 elacitarabina                             4-amino-1-{5-O-[(9E)-octadec-9-enoil]-β-D-arabinofuranosil}pirimidin-
                                           2(1H)-ona

                                           C27H45N3O6

                                                                                                                              NH2

                                                                                                                         N

                                           H3C                                                                  O    O        N
                                                                                                                     O
                                                                                                            O            HO


                                                                                                                    OH




                                                                                                                                  245
Recommended INN: List 62                                       WHO Drug Information Vol 23, No. 3, 2009




 elotuzumabum #
 elotuzumab                immunoglobulin G1-kappa, anti-[Homo sapiens SLAM family
                           member 7 (SLAM7, CD2 subset 1, CS1, CD2-like receptor-activating
                           cytotoxic cells, CRACC, 19A24, CD319), humanized monoclonal
                           antibody;
                           gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                           IGHV3-74*01 (81.60%) -IGHJ2*01, R120>Q) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01 (120-449)], (222-214')-disulfide with kappa light
                           chain (1'-214') [humanized V-KAPPA (Homo sapiens IGKV1-27*01
                           (84.20%) -IGKJ2*01, L124>V) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; (228-228'':231-231'')-bisdisulfide dimer

 elotuzumab                immunoglobuline G1-kappa, anti-[Homo sapiens membre 7 de la
                           famille SLAM (SLAM7, CD2 subset 1, CS1, CD2-like receptor-
                           activating cytotoxic cells, CRACC, 19A24, CD319), anticorps
                           monoclonal humanisé;
                           chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                           IGHV3-74*01 (81.60%) -IGHJ2*01, R120>Q) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne
                           légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-
                           27*01 (84.20%) IGKJ2*01, L124>V) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure

 elotuzumab                inmunoglobulina G1-kappa, anti-[Homo sapiens miembro 7 de la
                           familia SLAM (conocido como: SLAM7, CD2 subset 1, CS1, CD2-
                           like receptor-activating cytotoxic cells, CRACC, 19A24, CD319),
                           anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiens
                           IGHV3-74*01 (81.60%) -IGHJ2*01, R120>Q) [8.8.12] (1-119) -Homo
                           sapiens IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena
                           ligera kappa (1'-214') [V-KAPPA humanizada (Homo sapiens IGKV1-
                           27*01 (84.20%) IGKJ2*01, L124>V) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dímero(228-228'':231-231'')-bisdisulfuro

                           C6476H9982N1714O2016S42

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFDFS                  RYWMSWVRQA       PGKGLEWIGE          50
                           INPDSSTINY APSLKDKFII SRDNAKNSLY                  LQMNSLRAED       TAVYYCARPD         100
                           GNYWYFDVWG QGTLVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD         150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY         200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK         250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS         300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV         350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL         400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK          449

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS LSASVGDRVT ITCKASQDVG                  IAVAWYQQKP       GKVPKLLIYW          50
                           ASTRHTGVPD RFSGSGSGTD FTLTISSLQP                  EDVATYYCQQ       YSSYPYTFGQ         100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV         150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG         200
                           LSSPVTKSFN RGEC                                                                       214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        146-202       263-323  369-427
                                     22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-88'       134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 222-214' 222''-214'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''




246
WHO Drug Information Vol 23, No. 3, 2009                                                             Recommended INN: List 62


 farletuzumabum #
 farletuzumab                              immunoglobulin G1-kappa, anti-[Homo sapiens folate receptor 1
                                           (FOLR1, folate receptor alpha, FR-alpha, adult folate-binding protein,
                                           FBP, ovarian tumor-associated antigen MOv18)], humanized
                                           monoclonal antibody;
                                           gamma1 heavy chain (1-449) [humanized VH (Homo sapiens
                                           IGHV3-30*03 (82.70%) -(IGHD)-IGHJ5*01, L123>P) [8.8.12] (1-119)
                                           -Homo sapiens IGHG1*01 (120-449)], (222-217')-disulfide with
                                           kappa light chain (1'-217') [humanized V-KAPPA (Homo sapiens
                                           IGKV1-33*01 (80.20%) -IGKJ2*01, L124>V) [7.3.11] (1'-110') -Homo
                                           sapiens IGKC*01 (111'-217')]; (228-228'':231-231'')-bisdisulfide
                                           dimer


 farletuzumab                              immunoglobuline G1-kappa, anti-[Homo sapiens réceptor 1 du folate
                                           (FOLR1, folate receptor alpha, FR-alpha, adult folate-binding protein,
                                           FBP, ovarian tumor-associated antigen MOv18)], anticorps
                                           monoclonal humanisé;
                                           chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiens
                                           IGHV3-30*03 (82.70%) -(IGHD)-IGHJ5*01, L123>P) [8.8.12] (1-119)
                                           -Homo sapiens IGHG1*01 (120-449)], (222-217')-disulfure avec la
                                           chaîne légère kappa (1'-217') [V-KAPPA humanisé (Homo sapiens
                                           IGKV1-33*01 (80.20%) -IGKJ2*01, L124>V) [7.3.11] (1'-110') -Homo
                                           sapiens IGKC*01 (111'-217')]; dimère (228-228'':231-231'')-
                                           bisdisulfure

 farletuzumab                              inmunoglobulina G1-kappa, anti-[receptor 1 de folato de Homo
                                           sapiens (conocido como: FOLR1, folate receptor alpha, FR-alpha,
                                           adult folate-binding protein, FBP, ovarian tumor-associated antigen
                                           MOv18)], anticuerpo monoclonal humanizado;
                                           cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiens
                                           IGHV3-30*03 (82.70%) -(IGHD)-IGHJ5*01, L123>P) [8.8.12] (1-119)
                                           -Homo sapiens IGHG1*01 (120-449)], (222-217')-disulfuro con la
                                           cadena ligera kappa (1'-217') [V-KAPPA humanizada (Homo sapiens
                                           IGKV1-33*01 (80.20%) -IGKJ2*01, L124>V) [7.3.11] (1'-110') -Homo
                                           sapiens IGKC*01 (111'-217')]; dimero (228-228'':231-231'')-
                                           bisdisulfuro

                                           C6466H9928N1716O2020S42

                                           Heavy chain / Chaîne lourde / Cadena pesada
                                           EVQLVESGGG VVQPGRSLRL SCSASGFTFS                  GYGLSWVRQA       PGKGLEWVAM          50
                                           ISSGGSYTYY ADSVKGRFAI SRDNAKNTLF                  LQMDSLRPED       TGVYFCARHG         100
                                           DDPAWFAYWG QGTPVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD         150
                                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY         200
                                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK         250
                                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS         300
                                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV         350
                                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL         400
                                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK          449

                                           Light chain / Chaîne légère / Cadena ligera
                                           DIQLTQSPSS LSASVGDRVT ITCSVSSSIS                  SNNLHWYQQK       PGKAPKPWIY          50
                                           GTSNLASGVP SRFSGSGSGT DYTFTISSLQ                  PEDIATYYCQ       QWSSYPYMYT         100
                                           FGQGTKVEIK RTVAAPSVFI FPPSDEQLKS                  GTASVVCLLN       NFYPREAKVQ         150
                                           WKVDNALQSG NSQESVTEQD SKDSTYSLSS                  TLTLSKADYE       KHKVYACEVT         200
                                           HQGLSSPVTK SFNRGEC                                                                    217

                                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                           Intra-H 22-96        146-202       263-323   369-427
                                                     22''-96'' 146''-202'' 263''-323'' 369''-427''
                                           Intra-L 23'-89'      137'-197'
                                                    23'''-89''' 137'''-197'''
                                           Inter-H-L 222-217' 222''-217'''
                                           Inter-H-H 228-228'' 231-231''

                                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                           299, 299''




                                                                                                                                        247
Recommended INN: List 62                                  WHO Drug Information Vol 23, No. 3, 2009


 fidaxomicinum
 fidaxomicin               (3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-{[(6-deoxy-
                           4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-
                           β-D-mannopyranosyl)oxy]methyl}-12-{[6-deoxy-5-C-methyl-
                           4-O-(2-methylpropanoyl)-β-D-lyxo-hexopyranosyl]oxy}-11-ethyl-
                           8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyloxacycloocta-
                           3,5,9,13,15-pentaen-2-one

 fidaxomicine              (3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-({[6-déoxy-
                           4-O-(3,5-dichloro-2-éthyl-4,6-dihydroxybenzoyl)-2-O-méthyl-
                           β-D-mannopyranosyl]oxy}méthyl)-12-{[6-déoxy-5-C-méthyl-
                           4-O-(2-méthylpropanoyl)-β-D-lyxo-hexopyranosyl]oxy}-11-éthyl-
                           8-hydroxy-18-[(1R)-1-hydroxyéthyl]-9,13,15-
                           triméthyloxacyclooctadéca-3,5,9,13,15-pentaén-2-one

 fidaxomicina              3-{[(6-desoxi-4-O-(3,5-dicloro-2-etil-4,6-dihidroxibenzoil)-2-O-metil-
                           β-D-manopiranosil)oxi]metil}-12-{[6-desoxi-5-C-metil-
                           4-O-(2-metilpropanoil)-β-D-lixo-hexopiranosil]oxi}-11-etil-8-hidroxi-
                           18-[(1R)-1-hidroxietil]-9,13,15-trimetiloxacicloocta-3,5,9,13,15-
                           pentaen-2-ona

                           C52H74Cl2O18

                                                                     H OH
                                                                            CH3
                                                                            H
                                                                                  CH3
                                          CH3
                                                                     H3C
                                                     OO
                                                                            H
                                          OH H3CO                H3C            CH3       O
                                                          O     O
                                 O    O                                               O
                                                                  H
                                                      H3C                       CH3
                            HO                                                  OH HO
                                               CH3            H OH     O    O
                            Cl            Cl
                                     OH                              H3C    CH3



 figitumumabum #
 figitumumab               immunoglobulin G2-kappa, anti-[Homo sapiens insulin-like growth
                           factor 1 receptor (IGF-1R, CD221)], Homo sapiens monoclonal
                           antibody;
                           gamma2 heavy chain (1-450) [Homo sapiens VH (IGHV3-23*01
                           (93.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG2*01, CH3
                           K130>del (126-450)], (139-214')-disulfide with kappa light chain
                           (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (95.80%) -
                           IGKJ2*04) [6.3.9] (1'-107') -IGKC*01] (108'-214'); (227-227'':228-
                           228'':231-231'':234-234'')-tetradisulfide dimer

 figitumumab               immunoglobuline G2-kappa, anti-[Homo sapiens récepteur du
                           facteur de croissance analogue à l'insuline 1 (IGF-1R, CD221)],
                           Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma2 (1-450) [Homo sapiens VH (IGHV3-23*01
                           (93.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG2*01, CH3
                           K130>del (126-450)], (139-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (95.80%) -
                           IGKJ2*04) [6.3.9] (1'-107') -IGKC*01] (108'-214'); dimère (227-
                           227'':228-228'':231-231'':234-234'')-tétradisulfure


248
WHO Drug Information Vol 23, No. 3, 2009                                                             Recommended INN: List 62


 figitumumab                               inmunoglobulina G2-kappa, anti-[Homo sapiens receptor del factor
                                           de crecimiento insulínico tipo 1 de Homo sapiens (conocido como:
                                           IGF-1R, CD221)], anticuerpo monoclonal de Homo sapiens;
                                           cadena pesada gamma2 (1-450) [Homo sapiens VH (IGHV3-23*01
                                           (93.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG2*01, CH3
                                           K130>del (126-450)], (139-214')-disulfuro con la cadena ligera
                                           kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (95.80%) -
                                           IGKJ2*04) [6.3.9] (1'-107') -IGKC*01] (108'-214'); dímero (227-
                                           227'':228-228'':231-231'':234-234'')-tetradisulfuro


                                           C6450H9924N1732O2018S54

                                           Heavy chain / Chaîne lourde / Cadena pesada
                                           EVQLLESGGG LVQPGGSLRL SCTASGFTFS                  SYAMNWVRQA       PGKGLEWVSA          50
                                           ISGSGGTTFY ADSVKGRFTI SRDNSRTTLY                  LQMNSLRAED       TAVYYCAKDL         100
                                           GWSDSYYYYY GMDVWGQGTT VTVSSASTKG                  PSVFPLAPCS       RSTSESTAAL         150
                                           GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA                  VLQSSGLYSL       SSVVTVPSSN         200
                                           FGTQTYTCNV DHKPSNTKVD KTVERKCCVE                  CPPCPAPPVA       GPSVFLFPPK         250
                                           PKDTLMISRT PEVTCVVVDV SHEDPEVQFN                  WYVDGVEVHN       AKTKPREEQF         300
                                           NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK                  GLPAPIEKTI       SKTKGQPREP         350
                                           QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP         400
                                           MLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG         450

                                           Light chain / Chaîne légère / Cadena ligera
                                           DIQMTQFPSS LSASVGDRVT ITCRASQGIR                  NDLGWYQQKP       GKAPKRLIYA          50
                                           ASRLHRGVPS RFSGSGSGTE FTLTISSLQP                  EDFATYYCLQ       HNSYPCSFGQ         100
                                           GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV         150
                                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG         200
                                           LSSPVTKSFN RGEC                                                                       214

                                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                           Intra-H 22-96 152-208              265-325  371-429
                                                    22''-96'' 152''-208'' 265''-325'' 371''-429''
                                           Intra-L 23'-88'      134'-194'
                                                    23'''-88''' 134'''-194'''
                                           Inter-H-L 139-214' 139''-214'''
                                           Inter-H-H 227-227'' 228-228'' 231-231'' 234-234''

                                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                           301, 301''



 fosbretabulinum
 fosbretabulin                             2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl
                                           dihydrogen phosphate

 fosbrétabuline                            dihydrogénophosphate de 2-méthoxy-5-[(1Z)-2-(3,4,5-
                                           triméthoxyphényl)éthényl]phényle

 fosbretabulina                            dihidrògenofosfato de 2-metoxi-5-[(1Z)-2-(3,4,5-
                                           trimetoxifenil)etenil]fenilo

                                           C18H21O8P

                                           H3CO


                                           H3CO                                 O
                                                        OCH3                    P    OH
                                                                            O
                                                                                    OH
                                                                    OCH3



 fostamatinibum
 fostamatinib                              [6-({5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-
                                           2,2-dimethyl-3-oxo-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-
                                           4-yl]methyl dihydrogen phosphate




                                                                                                                                        249
Recommended INN: List 62                                      WHO Drug Information Vol 23, No. 3, 2009


 fostamatinib              dihydrogénophosphate de [6-({5-fluoro-2-[(3,4,5-
                           triméthoxyphényl)amino]pyrimidin-4-yl}amino)-2,2-diméthyl-3-oxo-
                           2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl]méthyle

 fostamatinib              dihidrògenofosfato de [6-({5-fluoro-2-[(3,4,5-
                           trimetoxifenil)amino]pirimidin-4-il}amino)-2,2-dimetil-3-oxo-
                           2,3-dihidro-4H-pirido[3,2-b][1,4]oxazin-4-il]metilo

                           C23H26FN6O9P

                                       OH
                              O
                                   P    OH
                                   O
                                                               F
                                                      H
                              O        N     N        N

                           H 3C                           N        N
                                       O
                             H3C
                                                              HN              OCH3


                                                                              OCH3
                                                                       OCH3



 indeglitazarum
 indeglitazar              3-[5-methoxy-1-(4-methoxybenzenesulfonyl)-1H-indol-3-yl]propanoic
                           acid

 indéglitazar              acide 3-{5-méthoxy-1-(4-méthoxybenzènesulfonyl)-1H-indol-
                           3-yl}propanoïque

 indeglitazar              ácido 3-[5-metoxi-1-(4-metoxibencenosulfonil)-1H-indol-
                           3-il]propanoico

                           C19H19NO6S

                                                  O
                                                      O
                           H3CO                   S
                                                      N

                                                                       CO2H


                                           H3CO



 ingenoli mebutatum
 ingenol mebutate          (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-5,5a-dihydroxy-
                           4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1a,2,5,5a,6,9,10,10a-
                           octahydro-1H-2,8a-methanocyclopenta[a]cyclpropa[e][10]annulen-
                           6-yl (2Z)-2-methylbut-2-enoate

 mébutate d'ingénol        (2Z)-2-méthylbut-2-énoate de (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-
                           5,5a-dihydroxy-4-(hydroxyméthyl)-1,1,7,9-tétraméthyl-11-oxo-
                           1a,2,5,5a,6,9,10,10a-octahydro-1H-2,8a-
                           méthanocyclopenta[a]cyclpropa[e][10]annulén-6-yle




250
WHO Drug Information Vol 23, No. 3, 2009                                                        Recommended INN: List 62


 mebutato de ingenol                       (2Z)-2-metilbut-2-enoato de (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-5,5a-
                                           dihidroxi-4-(hidroximetil)-1,1,7,9-tetrametil-11-oxo-
                                           1a,2,5,5a,6,9,10,10a-octahidro-1H-2,8a-
                                           metanociclopenta[a]ciclopropa[e][10]anulen-6-ilo

                                           C25H34O6

                                                                H3C
                                            CH3     O                         H   CH3
                                                         H
                                                         O                        O
                                                         HO                             H
                                               CH3       H                H
                                                         HO                               CH3
                                                        HO                        H     CH3


 laninamivirum
 laninamivir                               (2R,3R,4S)-3-acetamido-2-[(1R,2R)-2,3-dihydroxy-
                                           1-methoxypropyl]-4-guanidino-3,4-dihydro-2H-pyran-
                                           6-carboxylic acid

 laninamivir                               acide (2R,3R,4S)-3-acétamido-2-[(1R,2R)-2,3-dihydroxy-
                                           1-méthoxypropyl]-4-guanidino-3,4-dihydro-2H-pyran-
                                           6-carboxylique

 laninamivir                               ácido (2R,3R,4S)-3-acetamido-2-[(1R,2R)-2,3-dihidroxi-
                                           1-metoxipropil]-4-guanidino-3,4-dihidro-2H-piran-
                                           6-carboxílico

                                           C13H22N4O7

                                                   HO
                                                                  OH
                                              H3CO                H
                                                    H             O           CO2H
                                                     H
                                                    HN
                                                                              NH2
                                            H 3C            H
                                                                 H N
                                                        O          H
                                                                              NH


 lesogaberanum
 lesogaberan                               (2R)-3-amino-2-fluoropropylphosphinic acid

 lésogabéran                               acide [(2R)-3-amino-2-fluoropropyl]phosphinique

 lesogaberán                               ácido (2R)-3-amino-2-fluoropropilfosfínico

                                           C3H9FNO2P

                                                    H       F O       H
                                           H2N                    P
                                                                      OH


 limiglidolum
 limiglidole                               2-(2,3-dihydro-9H-imidazo[1,2-a]benzimidazol-9-yl)-
                                           N,N-dimethylethanamine




                                                                                                                     251
Recommended INN: List 62                                               WHO Drug Information Vol 23, No. 3, 2009


 limiglidole               2-(2,3-dihydro-9H-imidazo[1,2-a]benzimidazol-9-yl)-
                           N,N-diéthyléthanamine

 limiglidol                2-(2,3-dihidro-9H-imidazo[1,2-a]benzoimidazol-9-il)-
                           N,N-dimetiletanamina

                           C15H22N4

                               H3 C
                                                               N
                            H3C        N
                                                       N
                                                               N




 lotilibcinum
 lotilibcin                3-{(3S,6R,9R,12R,15S,18R,21S,24R,30S,33R,36S,40R)-33-[(1R)-2-
                           amino-1-hydroxy-2-oxoethyl]-12-(2-amino-2-oxoethyl)-6,18-bis(3-
                           aminopropyl)-24-benzyl-30,36-bis(hydroxymethyl)-9-(1H-indol-
                           3-ylmethyl)-4,25-dimethyl-40-(4-methylpentyl)-21-(2-methylpropyl)-
                           3-(propan-2-yl)-2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxo-
                           1-oxa-4,7,10,13,16,19,22,25,28,31,34,37-dodecaazatetracontan-
                           15-yl}propanoic acid

 lotilibcine               acide 3-{(3S,6R,9R,12R,15S,18R,21S,24R,30S,33R,36S,40R)-33-
                           [(1R)-2-amino-1-hydroxy-2-oxoéthyl]-12-(2-amino-2-oxoéthyl)-
                           6,18-bis(3-aminopropyl)-24-benzyl-30,36-bis(hydroxyméthyl)-
                           9-(1H-indol-3-ylméthyl)-4,25-diméthyl-40-(4-méthylpentyl)-
                           21-(2-méthylpropyl)-3-(propan-2-yl)-
                           2,5,8,11,14,17,20,23,26,29,32,35,38-tridécaoxo-1-oxa-
                           4,7,10,13,16,19,22,25,28,31,34,37-dodécaazatétracontan-
                           15-yl}propanoïque

 lotilibcina               ácido 3-{(3S,6R,9R,12R,15S,18R,21S,24R,30S,33R,36S,40R)-33-
                           [(1R)-2-amino-1-hidroxi-2-oxoetil]-12-(2-amino-2- oxoetil)-6,18-bis(3-
                           aminopropil)-24-bencil-30,36-bis(hidroximetil)-9-(1H-indol-3-ilmetil)-
                           4,25-dimetil-40-(4-metilpentil)-21-(2-metilpropil)-3-(propan-2-il)-
                           2,5,8,11,14,17,20,23,26,29,32,35,38-tridecaoxo-1-oxa-
                           4,7,10,13,16,19,22,25,28,31,34,37-dodecaazatetracontan-
                           15-il}propanoico

                           C73H111N17O21

                                                                                  O
                                   H2N                                                    NH2
                                                           H               O          H
                                                                   H                          H
                                       CH3 HN                      N                          N                NH
                                                                               N                      H
                             H3C        H                                      H
                                                               O   H                      O
                                                       O                                      O       NH
                                   O          NH                           CO2H                                O
                                                                                                                   CH3
                                                                                                  H
                                                   CH3                             H2N                     N
                                              N                                                   H3C                  CH3
                                      H                                                                            H
                                                           HO                         HO
                                          O                H           O              H           O        O       O     CH3
                                                                               H                      H
                                                  HN                           N
                                                                   N                          N                              CH3
                                                                   H H                        H
                                                       O           O            H O
                                                                               OH
                                                                       NH2


252
WHO Drug Information Vol 23, No. 3, 2009                                                                    Recommended INN: List 62


 macimorelinum
                                             2                                                      1
 macimorelin                               N -(2-amino-2-methylpropanoyl-N -[(1R)-1-formamido-2-(1H-indol-
                                           3-yl)ethyl]-D-tryptophanamide
                                             2                                                      1
 macimoréline                              N -(2-amino-2-méthylpropanoyl-N -[(1R)-1-formamido-2-(1H-indol-
                                           3-yl)éthyl]-D-tryptophanamide
                                             2                                              1
 macimorelina                              N -(2-amino-2-metilpropanoil-N -[(1R)-1-formamido-2-(1H-indol-
                                           3-il)etil]-D-triptofanamide

                                           C26H30N6O3



                                                                                    NH


                                             H3C CH3                O           H       O
                                                        H
                                                        N
                                            H2N                         N       N               H
                                                                        H       H
                                                    O           H



                                                                N
                                                                H


 namitecanum
 namitecan                                 (4S)-11-{(E)-[(2-aminoethoxy)imino]methyl}-4-ethyl-4-hydroxy-
                                           1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-
                                           3,14(4H)-dione

 namitécan                                 (4S)-11-{(E)-[(2-aminoéthoxy)imino]méthyl}-4-éthyl-4-hydroxy-
                                           1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléine-
                                           3,14(4H)-dione

 namitecán                                 (4S)-11-{(E)-[(2-aminoetoxi)imino]metil}-4-etil-4-hidroxi-1,12-dihidro-
                                           14H-pirano[3',4':6,7]indolizino[1,2-b]quinolina-3,14(4H)-diona

                                           C23H22N4O5

                                            H2 N                                         O
                                                        O
                                                            N                       N                   O

                                                                                                            O
                                                                            N                   HO          CH3



 necitumumabum #
 necitumumab                               immunoglobulin G1-kappa, anti-[Homo sapiens epidermal growth
                                           factor receptor (EGFR, ERBB1, HER1)], Homo sapiens monoclonal
                                           antibody;
                                           gamma1 heavy chain (1-451) [Homo sapiens VH (IGHV4-30-4*01
                                           (96.00%) -(IGHD)-IGHJ4*01) [10.7.13] (1-121) -IGHG1*03, CH1
                                           F5>L (122-451)], (224-214')-disulfide with kappa light chain (1'-214')
                                           [Homo sapiens V-KAPPA (IGKV3-11*01 (93.70%) -IGKJ4*01,
                                           V124>A) [6.3.9] (1’-107’) -IGKC*01 (108’-214’)]; (230-230'':233-
                                           233'')-bisdisulfide dimer




                                                                                                                                 253
Recommended INN: List 62                                         WHO Drug Information Vol 23, No. 3, 2009


 necitumumab                 immunoglobuline G1-kappa, anti-[Homo sapiens récepteur du
                             facteur de croissance épidermique (EGFR, ERBB1, HER1)], Homo
                             sapiens anticorps monoclonal;
                             chaîne lourde gamma1 (1-451) [Homo sapiens VH (IGHV4-30-4*01
                             (96.00%) -(IGHD)-IGHJ4*01) [10.7.13] (1-121) -IGHG1*03, CH1
                             F5>L (122-451)], (224-214')-disulfure avec la chaîne légère kappa
                             (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (93.70%) -
                             IGKJ4*01, V124>A) [6.3.9] (1’-107’) -IGKC*01 (108’-214’)]; dimère
                             (230-230'':233-233'')-bisdisulfure

 necitumumab                 inmunoglobulina G1-kappa, anti-[receptor del factor de crecimiento
                             epidérmico de Homo sapiens (conocido como: EGFR, ERBB1,
                             HER1)], anticuerpo monoclonal de Homo sapiens;
                             cadena pesada gamma1 (1-451) [Homo sapiens VH (IGHV4-30-
                             4*01 (96.00%) -(IGHD)-IGHJ4*01) [10.7.13] (1-121) -IGHG1*03,
                             CH1 F5>L (122-451)], (224-214')-disulfuro con la cadena ligera
                             kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (93.70%) -
                             IGKJ4*01, V124>A) [6.3.9] (1’-107’) -IGKC*01 (108’-214’)]; dímero
                             (230-230'':233-233'')-bisdisulfuro

                             C6436H9958N1702O2020S42

                              Heavy chain / Chaîne lourde / Cadena pesada
                              QVQLQESGPG LVKPSQTLSL TCTVSGGSIS                  SGDYYWSWIR       QPPGKGLEWI          50
                              GYIYYSGSTD YNPSLKSRVT MSVDTSKNQF                  SLKVNSVTAA       DTAVYYCARV         100
                              SIFGVGTFDY WGQGTLVTVS SASTKGPSVL                  PLAPSSKSTS       GGTAALGCLV         150
                              KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ         200
                              TYICNVNHKP SNTKVDKRVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK         250
                              PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY         300
                              NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP         350
                              QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP         400
                              VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG         450
                              K                                                                                     451

                              Light chain / Chaîne légère / Cadena ligera
                              EIVMTQSPAT LSLSPGERAT LSCRASQSVS                  SYLAWYQQKP       GQAPRLLIYD          50
                              ASNRATGIPA RFSGSGSGTD FTLTISSLEP                  EDFAVYYCHQ       YGSTPLTFGG         100
                              GTKAEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV         150
                              DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG         200
                              LSSPVTKSFN RGEC                                                                       214

                              Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                              Intra-H 22-97       148-204        265-325  371-429
                                       22''-97'' 148''-204'' 265''-325'' 371''-429''
                              Intra-L 23'-88'      134'-194'
                                       23'''-88''' 134'''-194'''
                              Inter-H-L 224-214' 224''-214'''
                              Inter-H-H 230-230'' 233-233''

                              N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                              301, 301''




 oportuzumabum monatoxum #
 oportuzumab monatox         immunoglobulin scFv fusion protein, anti-[Homo sapiens tumor-
                             associated calcium signal transducer 1 (TACSTD1, gastrointestinal
                             tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-
                             2, epithelial cell adhesion molecule Ep-CAM, KSA, KS1/4 antigen,
                             M4S1, tumor antigen 17-1A, CD326)] humanized monoclonal
                             antibody scFv fused with Pseudomonas aeruginosa exotoxin A;
                             hexahistidyl -humanized scFv [V-KAPPA (Homo sapiens IGKV1-
                             39*01 (78%)- IGKJ1*01, I126>L) [11.3.9] (7-118) -26-mer linker -VH
                             (Homo sapiens IGHV7-4-1*02 -(IGHD)-IGHJ4*01, V124>L) [8.8.9]
                             (145-260)] -20-mer linker -Pseudomonas aeruginosa exotoxin A
                             (ETA) [277-633 precursor fragment, containing domain II (281-393)
                             with furin proteolytic cleavage site (302-313), domain Ib (394-433),
                             domain III (434-637)] (281-637) -hexahistidyl-lysyl-aspartyl-glutamyl-
                             leucyl



254
WHO Drug Information Vol 23, No. 3, 2009                                                             Recommended INN: List 62




 oportuzumab monatox                       immunoglobuline scFv protéine de fusion, anti-[Homo sapiens
                                           transducteur 1 du signal calcium associé aux tumeurs (TACSTD1,
                                           protéine 2 associée aux tumeurs gastrointestinales, GA733-2,
                                           glycoprotéine épithéliale 2, EGP-2, molécule d’adhésion des cellules
                                           épithéliales Ep-CAM, KSA, antigène KS1/4, M4S1, antigène tumoral
                                           17-1A, CD326)] anticorps monoclonal humanisé scFv fusionné avec
                                           l’exotoxine A de Pseudomonas aeruginosa;
                                           hexahistidyl -scFv humanisé [V-KAPPA (Homo sapiens IGKV1-
                                           39*01 (78%)- IGKJ1*01, I126>L) [11.3.9] (7-118) -linker 26-mer -VH
                                           (Homo sapiens IGHV7-4-1*02 -(IGHD)- IGHJ4*01, V124>L) [8.8.9]
                                           (145-260)] -linker 20-mer -Pseudomonas aeruginosa exotoxine A
                                           (ETA) [fragment précurseur 277-633, comprenant domaine II (281-
                                           393) dont site de clivage protéolytique par la furine (302-313),
                                           domaine Ib (394-433), domaine III (434-637)] (281-637) -
                                           hexahistidyl-lysyl-aspartyl-glutamyl-leucyl

 oportuzumab monatox                       inmunoglobulina scFv proteína de fusión, anti-[Homo sapiens
                                           transductor 1 de la señal de calcio asociado a los tumores
                                           (TACSTD1, proteína 2 asociada a los tumores gastrointestinales,
                                           GA733-2, glicoproteína epitelial 2, EGP-2, molécula de adhesión de
                                           las células epiteliales Ep-CAM, KSA, antígeno KS1/4, M4S1,
                                           antígeno tumoral 17-1A, CD326)] anticuerpo monoclonal
                                           humanizado scFv fusionado con la exotoxina A de Pseudomonas
                                           aeruginosa;
                                           hexahistidil -scFv humanizado [V-KAPPA (Homo sapiens IGKV
                                           1-39*01 (78%)- IGKJ1*01, I126>L) [11.3.9] (7-118) -linker 26-mer -
                                           VH (Homo sapiens IGHV7-4-1*02 -(IGHD)- IGHJ4*01, V124>L)
                                           [8.8.9] (145-260)] -linker 20-mer -Pseudomonas aeruginosa
                                           exotoxina A (ETA) [fragmento precursor 277-633, que comprende el
                                           dominio II (281-393) con el sitio de ruptura proteolítica por furina
                                           (302-313), dominio Ib (394-433), dominio III (434-637)] (281-637) -
                                           hexahistidil-lisil-aspartil-glutamil-leucil

                                           C3072H4723N877O952S12
                                           scFv fusion protein / scFv protéine de fusion / scFv proteína de fusión
                                           HHHHHHDIQM TQSPSSLSAS VGDRVTITCR STKSLLHSNG ITYLYWYQQK                               50
                                           PGKAPKLLIY QMSNLASGVP SRFSSSGSGT DFTLTISSLQ PEDFATYYCA                              100
                                           QNLEIPRTFG QGTKVELKRA TPSHNSHQVP SAGGPTANSG TSGSEVQLVQ                              150
                                           SGPGLVQPGG SVRISCAASG YTFTNYGMNW VKQAPGKGLE WMGWINTYTG                              200
                                           ESTYADSFKG RFTFSLDTSA SAAYLQINSL RAEDTAVYYC ARFAIKGDYW                              250
                                           GQGTLLTVSS EFGGAPEFPK PSTPPGSSGL EGGSLAALTA HQACHLPLET                              300
                                           FTRHRQPRGW EQLEQCGYPV QRLVALYLAA RLSWNQVDQV IRNALASPGS                              350
                                           GGDLGEAIRE QPEQARLALT LAAAESERFV RQGTGNDEAG AASADVVSLT                              400
                                           CPVAAGECAG PADSGDALLE RNYPTGAEFL GDGGDVSFST RGTQNWTVER                              450
                                           LLQAHRQLEE RGYVFVGYHG TFLEAAQSIV FGGVRARSQD LDAIWRGFYI                              500
                                           AGDPALAYGY AQDQEPDARG RIRNGALLRV YVPRSSLPGF YRTGLTLAAP                              550
                                           EAAGEVERLI GHPLPLRLDA ITGPEEEGGR LETILGWPLA ERTVVIPSAI                              600
                                           PTDPRNVGGD LDPSSIPDKE QAISALPDYA SQPGKPPHHH HHHKDEL                                 647

                                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                           29-99 166-240 294-316 401-408

                                           N-glycosylation site / Site de N-glycosylation / Posición de N-glicosilación
                                           445




                                                                                                                                        255
Recommended INN: List 62                                                WHO Drug Information Vol 23, No. 3, 2009


 panobacumabum #
 panobacumab               immunoglobulin M-kappa [Pseudomonas aeruginosa serotype IATS
                           O11], Homo sapiens monoclonal antibody with a Mus musculus J
                           chain;
                           mu heavy chain (1-569) [Homo sapiens VH (IGHV3-74*01 (92.90%)
                           -(IGHD)-IGHJ3*01) [8.7.10] (1-116) -IGHM*03 (117-569)], (130-
                           219’)-disulfide with kappa light chain (1'-219') [Homo sapiens
                           V-KAPPA (IGKV2-30*01 (100%) -IGKJ4*01) [11.3.9] (1'-112') -
                           IGKC*01 (113'-219'); (330-330”)-monodisulfide dimer; (407-
                           407”:568-568”)-octadisulfide between 5 dimers (a-e) to form a
                           pentamer; pentamer (407''a-15'''':568e-69'''')-bisdisulfide with Mus
                           musculus J chain (1''''-138'''')

 panobacumab               immunoglobuline M-kappa [Pseudomonas aeruginosa sérotype IATS
                           O11], Homo sapiens anticorps monoclonal avec la chaîne J de Mus
                           musculus;
                           chaîne lourde mu (1-569) [Homo sapiens VH (IGHV3-74*01(92.90%)
                           -(IGHD)-IGHJ3*01) [8.7.10] (1-116) -IGHM*03 (117-569)], (130-
                           219’)-disulfure avec la chaîne légère kappa (1'-219') [Homo sapiens
                           V-KAPPA (IGKV2-30*01 (100%) -IGKJ4*01) [11.3.9] (1'-112') -
                           IGKC*01 (113'-219'); dimère (330-330”)-monodisulfure; pentamère
                           fait de 5 dimères (407-407”:568-568”)-octadisulfure; pentamère
                           (407''a-15'''':568e-69'''')-bisdisulfure avec la chaîne J de Mus
                           musculus (1''''-138'''')

 panobacumab               inmunoglobulina M-kappa [Pseudomonas aeruginosa serotipo IATS
                           O11], anticuerpo monoclonal de Homo sapiens con una cadena J de
                           Mus musculus ;
                           cadena pesada mu (1-569) [Homo sapiens VH (IGHV3-
                           74*01(92.90%) -(IGHD)-IGHJ3*01) [8.7.10] (1-116) -IGHM*03 (117-
                           569)], (130-219’)-disulfuro con la cadena ligera kappa (1'-219')
                           [Homo sapiens V-KAPPA (IGKV2-30*01 (100%) -IGKJ4*01) [11.3.9]
                           (1'-112') -IGKC*01 (113'-219']; dímero (330-330”)-monodisulfuro;
                           pentámero compuesto de 5 dímeros (407-407”:568-568”)-
                           octadisulfuro; pentámero (407''a-15'''':568e-69'''')-bisdisulfuro con la
                           cadena J de Mus musculus (1''''-138'''')

                           C38714H60189N10637O12187S322
                           Heavy chain / Chaîne lourde / Cadena pesada
                           EEQVVESGGG FVQPGGSLRL SCAASGFTFS                  PYWMHWVRQA         PGKGLVWVSR     50
                           INSDGSTYYA DSVKGRFTIS RDNARNTLYL                  QMNSLRAEDT         AVYYCARDRY    100
                           YGPEMWGQGT MVTVSSGSAS APTLFPLVSC                  ENSPSDTSSV         AVGCLAQDFL    150
                           PDSITFSWKY KNNSDISSTR GFPSVLRGGK                  YAATSQVLLP         SKDVMQGTDE    200
                           HVVCKVQHPN GNKEKNVPLP VIAELPPKVS                  VFVPPRDGFF         GNPRKSKLIC    250
                           QATGFSPRQI QVSWLREGKQ VGSGVTTDQV                  QAEAKESGPT         TYKVTSTLTI    300
                           KESDWLSQSM FTCRVDHRGL TFQQNASSMC                  VPDQDTAIRV         FAIPPSFASI    350
                           FLTKSTKLTC LVTDLTTYDS VTISWTRQNG                  EAVKTHTNIS         ESHPNATFSA    400
                           VGEASICEDD WNSGERFTCT VTHTDLPSPL                  KQTISRPKGV         ALHRPDVYLL    450
                           PPAREQLNLR ESATITCLVT GFSPADVFVQ                  WMQRGQPLSP         EKYVTSAPMP    500
                           EPQAPGRYFA HSILTVSEEE WNTGETYTCV                  VAHEALPNRV         TERTVDKSTG    550
                           KPTLYNVSLV MSDTAGTCY                                                               569

                           Light chain / Chaîne légère / Cadena ligera
                           DVVMTQSPLS LPVTLGQPAS ISCRSSQSLV                  YSDGNTYLNW         FQQRPGQSPR 50
                           RLIYKVSNRD SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV         YYCMQGTHWP 100
                           LTFGGGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL         LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD         YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                            219

                           J chain / Chaîne J / Cadena J
                           GDDEATILAD NKCMCTRVTS RIIPSTEDPN EDIVERNIRI VVPLNNRENI 50
                           SDPTSPLRRN FVYHLSDVCK KCDPVEVELE DQVVTATQSN ICNEDDGVPE 100
                           TCYMYDRNKC YTTMVPLRYH GETKMVQAAL TPDSCYPD              138

                           Disulfide bridges location / Position des ponts disulfure /
                           Posiciones de los puentes disulfuro Intra chain
                           -IG monomer
                           Intra-H 22-95        144-204 250-313             360-419 467-529
                                    22''-95'' 144''-204'' 250''-313'' 360''-419'' 467''-529''
                           Intra-L 23'-93' 139'-199' 23'''-93''' 139'''-199'''
                           Inter-H-L 130-219' 130''-219'''
                           Inter-H-H 330-330''
                           -J chain and pentamer
                           Intra-J 13''''-102'''' 72''''-92'''' 110''''-135''''
                           Inter-H-H 407a-407''b 407b-407''c 407c-407''d 407d-407''e
                             568a-568''b 568b-568''c 568c-568''d 568d-568''e
                           Inter-H-J 407''a-15'''' 568e-69''''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           IG monomer : 162, 162'', 325, 325'', 388, 388'', 395, 395'', 556, 556''
                           J chain: 49''''




256
WHO Drug Information Vol 23, No. 3, 2009                                                 Recommended INN: List 62




 pitolisantum
 pitolisant                                1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine

 pitolisant                                1-{3-[3-(4-chlorophényl)propoxy]propyl}pipéridine

 pitolisant                                1-{3-[3-(4-clorofenil)propoxi]propil}piperidina

                                           C17H26ClNO

                                                 N            O

                                                                                    Cl



 pozaniclinum
 pozanicline                               2-methyl-3-{[(2S)-pyrrolidin-2-yl]methoxy}pyridine

 pozanicline                               2-méthyl-3-{[(2S)-pyrrolidin-2-yl]méthoxy}pyridine

 pozaniclina                               2-metil-3-{[(2S)-pirrolidin-2-il]metoxi}piridina

                                           C11H16N2O

                                                     H3C     N
                                             H
                                             N
                                                         O
                                                     H




 racotumomabum #
 racotumomab                               immunoglobulin G1-kappa, anti-idiotype anti-[anti-
                                           (N-glycolylneuraminic acid (NeuGc, NGNA)-gangliosides GM3) Mus
                                           musculus IgM-kappa monoclonal antibody P3], Mus musculus
                                           monoclonal antibody;
                                           gamma1 heavy chain (1-445) [Mus musculus VH (IGHV1S56*01 -
                                           (IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*01, CH1 E84.2>Q,
                                           N-glycosylation sites CH2 N84.4, CH3 N84.4 (122-445)], (223-214’)-
                                           disulfide with kappa light chain (1'-214') [Mus musculus V-KAPPA
                                           (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (1'-107') -IGKC1*01 (108'-214')];
                                           (225-225'':228-228'':230-230'')-trisdisulfide dimer

 racotumomab                               immunoglobuline G1-kappa, anti-idiotype anti-[anti-(acide
                                           N-glycolylneuraminique (NeuGc, NGNA)-gangliosides GM3)
                                           anticorps monoclonal IgM-kappa murin P3], Mus musculus anticorps
                                           monoclonal; chaîne lourde gamma1 (1-445) [Mus musculus VH
                                           (IGHV1S56*01 -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*01, CH1
                                           E84.2>Q, sites de N-glycosylation CH2 N84.4, CH3 N84.4 (122-
                                           445)], (223-214’)-disulfure avec la chaîne légère kappa (1'-214')
                                           [Mus musculus V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9]
                                           (1'-107') -IGKC1*01 (108'-214')]; dimère (225-225'':228-228'':230-
                                           230'')-trisdisulfure




                                                                                                              257
Recommended INN: List 62                                      WHO Drug Information Vol 23, No. 3, 2009


 racotumomab               inmunoglobulina G1-kappa, anti-idiotipo anti-[anti-(ácido
                           N-glicolilneuramínico (NeuGc, NGNA)-gangliósidos GM3) anticuerpo
                           monoclonal murino P3 IgM-kappa], anticuerpo monoclonal de Mus
                           musculus;
                           cadena pesada gamma1 (1-445) [Mus musculus VH (IGHV1S56*01
                           -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -IGHG1*01, CH1 E84.2>Q,
                           posiciones de N-glicosilación CH2 N84.4, CH3 N84.4 (122-445)],
                           (223-214’)-disulfuro con la cadena ligera kappa (1'-214') [Mus
                           musculus V-KAPPA (IGHKV10-96*01 -IGKJ1*01) [6.3.9] (1'-107') -
                           IGKC1*01 (108'-214')]; dímero (225-225'':228-228'':230-230'')-
                           trisdisulfuro

                           C6476H9922N1712O2048S50

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQQSGAE LVKPGASVKL SCKASGYTFT                  SYDINWVRQR       PEQGLEWIGW          50
                           IFPGDGSTKY NEKFKGKATL TTDKSSSTAY                  MQLSRLTSED       SAVYFCARED         100
                           YYDNSYYFDY WGQGTTLTVS SAKTTPPSVY                  PLAPGSAAQT       NSMVTLGCLV         150
                           KGYFPEPVTV TWNSGSLSSG VHTFPAVLQS                  DLYTLSSSVT       VPSSPRPSET         200
                           VTCNVAHPAS STKVDKKIVP RDCGCKPCIC                  TVPEVSSVFI       FPPKPKDVLT         250
                           ITLTPKVTCV VVDISKDDPE VQFSWFVDDV                  EVHTAQTQPR       EEQFNSTFRS         300
                           VSELPIMHQD WLNGKEFKCR VNSAAFPAPI                  EKTISKTKGR       PKAPQVYTIP         350
                           PPKEQMAKDK VSLTCMITDF FPEDITVEWQ                  WNGQPAENYK       NTQPIMNTNG         400
                           SYFVYSKLNV QKSNWEAGNT FTCSVLHEGL                  HNHHTEKSLS       HSPGK              445

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQTTSS LSASLGDRVT ISCRASQDIS                  NYLNWYQQKP       DGTVKLLIYY          50
                           TSRLHSGVPS RFSGSGSGTD YSLTISNLEQ                  EDIATYFCQQ       GNTLPWTFGG         100
                           GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA                  SVVCFLNNFY       PKDINVKWKI         150
                           DGSERQNGVL NSWTDQDSKD STYSMSSTLT                  LTKDEYERHN       SYTCEATHKT         200
                           STSPIVKSFN RNEC                                                                       214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 148-203              259-319  365-423
                                    22''-96'' 148''-203'' 259''-319'' 365''-423''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 223-214' 223''-214'''
                           Inter-H-H 225-225'' 228-228'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           295, 295''




 ramucirumabum #
 ramucirumab               immunoglobulin G1-kappa, anti-[Homo sapiens vascular endothelial
                           growth factor receptor 2 (VEGFR2, KDR, kinase insert domain
                           receptor, FLK1, CD309) extracellular domain], Homo sapiens
                           monoclonal antibody;
                           gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV3-
                           21*01(99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) - IGHG1*03,
                           R120>K (117-446)], (219-214')-disulfide with kappa light chain
                           (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -
                           IGKJ4*01, E125>D) [6.3.9] (1'-107') -IGKC*01, R1.4>G (108'-214')];
                           (225-225'':228-228'')-bisdisulfide dimer

 ramucirumab               immunoglobuline G1-kappa, anti-[Homo sapiens récepteur 2 du
                           facteur de croissance endothélial vasculaire (VEGFR2, KDR,
                           récepteur à domaine insert kinase, FLK1, CD309) domaine
                           extracellulaire], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV3-21*01
                           (99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03, R120>K
                           (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214')
                           [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01,
                           E125>D) [6.3.9] (1'-107') -IGKC*01, R1.4>G (108'-214')]; dimère
                           (225-225'':228-228'')-bisdisulfure




258
WHO Drug Information Vol 23, No. 3, 2009                                                             Recommended INN: List 62


 ramucirumab                               inmunoglobulina G1-kappa, anti-[receptor 2 del factor de crecimiento
                                           endotelial vascular de Homo sapiens (conocido como: VEGFR2,
                                           KDR, receptor con dominio inserto-kinasa, FLK1, CD309) dominio
                                           extracelular], anticuerpo monoclonal de Homo sapiens;
                                           cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV3-21*01
                                           (99.00%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03, R120>K
                                           (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214')
                                           [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01,
                                           E125>D) [6.3.9] (1'-107') -IGKC*01, R1.4>G (108'-214')]; dímero
                                           (225-225'':228-228'')-bisdisulfuro

                                           C6374H9896N1692O1996S46

                                           Heavy chain / Chaîne lourde / Cadena pesada
                                           EVQLVQSGGG LVKPGGSLRL SCAASGFTFS                  SYSMNWVRQA       PGKGLEWVSS        50
                                           ISSSSSYIYY ADSVKGRFTI SRDNAKNSLY                  LQMNSLRAED       TAVYYCARVT       100
                                           DAFDIWGQGT MVTVSSASTK GPSVFPLAPS                  SKSTSGGTAA       LGCLVKDYFP       150
                                           EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTQTYICN       200
                                           VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA                  PELLGGPSVF       LFPPKPKDTL       250
                                           MISRTPEVTC VVVDVSHEDP EVKFNWYVDG                  VEVHNAKTKP       REEQYNSTYR       300
                                           VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP                  IEKTISKAKG       QPREPQVYTL       350
                                           PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                                           GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                                           Light chain / Chaîne légère / Cadena ligera
                                           DIQMTQSPSS VSASIGDRVT ITCRASQGID                  NWLGWYQQKP       GKAPKLLIYD 50
                                           ASNLDTGVPS RFSGSGSGTY FTLTISSLQA                  EDFAVYFCQQ       AKAFPPTFGG 100
                                           GTKVDIKGTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                           LSSPVTKSFN RGEC                                                               214

                                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                           Intra-H 22-96 143-199              260-320  366-424
                                                    22''-96'' 143''-199'' 260''-320'' 366''-424''
                                           Intra-L 23'-88' 134'-194'
                                                    23'''-88''' 134'''-194'''
                                           Inter-H-L 219-214' 219''-214'''
                                           Inter-H-H 225-225'' 228-228''

                                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                           296, 296''


 regorafenibum
 regorafenib                               4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-
                                           3-fluorophenoxy]-N-methylpyridine-2-carboxamide

 régorafénib                               4-[4-({[4-chloro-3-(trifluorométhyl)phényl]carbamoyl}amino)-
                                           3-fluorophénoxy]-N-méthylpyridine-2-carboxamide

 regorafenib                               4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-
                                           N-metilpiridina-2-carboxamida

                                           C21H15ClF4N4O3

                                                            H       H
                                                            N       N
                                                                                                 N
                                                                                                         H
                                                                O                                        N
                                           Cl                        F               O                       CH3
                                                    CF3                                              O


 riferminogenum pecaplasmidum #
 riferminogene pecaplasmid                 plasmid DNA vector with a conditional origin of replication (pCOR)
                                           expressing a hybrid protein consisting of a secretion signal peptide
                                           from human fibroblast interferon ß fused to the N-terminus of a
                                           truncated form of the human fibroblast growth factor-1 (FGF-1) from
                                           amino acid 21 to 154 under the control of a cytomegalovirus
                                           promoter



                                                                                                                                        259
Recommended INN: List 62                               WHO Drug Information Vol 23, No. 3, 2009




 riferminogène pécaplasmide   vecteur constitué d'ADN plasmidique avec origine de réplication
                              conditionnelle (pCOR), exprimant une protéine hybride constituée
                              d'un peptide signal de sécrétion de l'interféron ß de fibroblaste
                              humain, fusionnée à l'extrémité N-terminale de la forme tronquée du
                              facteur de croissance des fibroblastes-1 (FGF-1) de l'acide aminé 21
                              au 154, sous le contrôle d'un promoteur de cytomégalovirus

 riferminogén pecaplásmido    vector de DNA plasmídico con un origen de replicación
                              condicionado (pCOR) que expresa una proteína híbrida que consiste
                              en el péptido señal de secreción del interferón ß de fibroblastos
                              humanos, fusionado con la región amino terminal de una forma
                              truncada del factor de crecimiento de fibroblastos humano-1
                              (FGF-1), desde el aminoácido 21 al 154, bajo el control de un
                              promotor de citomegalovirus




 robatumumabum #
 robatumumab                  immunoglobulin G1-kappa, anti-[Homo sapiens insulin-like growth
                              factor I receptor (IGF-1R, CD221)], Homo sapiens monoclonal
                              antibody;
                              gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-48*03
                              (87.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -IGHG1*01 (119-448)],
                              (221-214')-disulfide with kappa light chain (1'-214') [Homo sapiens
                              V-KAPPA (IGKV3-20*01 (83.30%) -IGKJ1*01) [6.3.9] (1'-107') -
                              IGKC*01] (108'-214'); (227-227'':230-230'')-bisdisulfide dimer

 robatumumab                  immunoglobuline G1-kappa, anti-[Homo sapiens récepteur du
                              facteur de croissance analogue à l'insuline 1 (IGF-1R, CD221)],
                              Homo sapiens anticorps monoclonal;
                              chaîne lourde gamma1 (1-448) [Homo sapiens VH (IGHV3-48*03
                              (87.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -IGHG1*01 (119-448)],
                              (221-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo
                              sapiens V-KAPPA (IGKV3-20*01 (83.30%) -IGKJ1*01) [6.3.9]
                              (1'-107') -IGKC*01] (108'-214'); dimère (227-227'':230-230'')-
                              bisdisulfure

 robatumumab                  inmunoglobulina G1-kappa, anti-[receptor del factor de crecimiento
                              insulínico tipo 1 de Homo sapiens (IGF-1R, CD221)], anticuerpo
                              monoclonal de Homo sapiens;
                              cadena pesada gamma1 (1-448) [Homo sapiens VH (IGHV3-48*03
                              (87.80%) -(IGHD)-IGHJ6*01) [8.7.12] (1-118) -IGHG1*01 (119-448)],
                              (221-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo
                              sapiens V-KAPPA (IGKV3-20*01 (83.30%) -IGKJ1*01) [6.3.9]
                              (1'-107') -IGKC*01] (108'-214'); dímero (227-227'':230-230'')-
                              bisdisulfuro




260
WHO Drug Information Vol 23, No. 3, 2009                                                              Recommended INN: List 62


                                           C6418H9960N1732O1992S42

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVQSGGG LVKPGGSLRL SCAASGFTFS                  SFAMHWVRQA       PGKGLEWISV        50
                                            IDTRGATYYA DSVKGRFTIS RDNAKNSLYL                  QMNSLRAEDT       AVYYCARLGN       100
                                            FYYGMDVWGQ GTTVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                            FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                            CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC                  PAPELLGGPS       VFLFPPKPKD       250
                                            TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                            TLPPSRDELT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                            SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPGT LSVSPGERAT LSCRASQSIG                  SSLHWYQQKP       GQAPRLLIKY 50
                                            ASQSLSGIPD RFSGSGSGTD FTLTISRLEP                  EDFAVYYCHQ       SSRLPHTFGQ 100
                                            GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                               214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-95 145-201              262-322  368-426
                                                     22''-95'' 145''-201'' 262''-322'' 368''-426''
                                            Intra-L 23'-88' 134'-194'
                                                     23'''-88''' 134'''-194'''
                                            Inter-H-L 221-214' 221''-214'''
                                            Inter-H-H 227-227'' 230-230''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            298, 298''


 selumetinibum
 selumetinib                               5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-
                                           1-methyl-1H-benzimidazole-6-carboxamide

 sélumétinib                               5-[(4-bromo-2-chlorophényl)amino]-4-fluoro-N-(2-hydroxyéthoxy)-
                                           1-méthyl-1H-benzimidazole-6-carboxamide

 selumetinib                               5-[(4-bromo-2-clorofenil)amino]-4-fluoro-N-(2-hidroxietoxi)-1-metil-
                                           1H-benzoimidazol-6-carboxamida

                                           C17H15BrClFN4O3

                                                                 Br




                                                         F                Cl

                                                N                NH
                                                                      H
                                                                      N              OH
                                                N                         O
                                            H3C                  O


 serlopitantum
 serlopitant                               3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-
                                           bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-
                                           2H-isoindol-2-yl]cyclopent-2-en-1-one

 serlopitant                               3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-
                                           bis(trifluorométhyl)phényl]éthoxy}-4-(4-fluorophényl)octahydro-
                                           2H-isoindol-2-yl]cyclopent-2-énone

 serlopitant                               3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi}-
                                           4-(4-fluorofenil)octahidro-2H-isoindol-2-il]ciclopent-2-en-1-ona




                                                                                                                                         261
Recommended INN: List 62                                      WHO Drug Information Vol 23, No. 3, 2009


                           C29H28F7NO2

                                                  H
                           O
                                                                H   CH3
                                          N
                                                                                  CF3
                                                              O
                                                  H      H
                                                        H

                                                                          CF3
                                              F


 siltuximabum #
 siltuximab                immunoglobulin G1-kappa, anti-[Homo sapiens interleukin 6 (IL6,
                           IL-6)], chimeric monoclonal antibody;
                           gamma1 heavy chain (1-449) [Mus musculus VH (IGHV5-9-4*01 -
                           (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                           449)], (222-213')-disulfide with kappa light chain (1'-213') [Mus
                           musculus V-KAPPA (IGKV4-55*01 –IGKJ2*01) [5.3.9] (1'-106') -
                           Homo sapiens IGKC*01 (107'-213')]; (228-228'':231-231'')-
                           bisdisulfide dimer

 siltuximab                immunoglobuline G1-kappa, anti-[Homo sapiens interleukine 6 (IL6,
                           IL-6)], anticorps monoclonal chimérique;
                           chaîne lourde gamma1 (1-449) [Mus musculus VH (IGHV5-9-4*01 -
                           (IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                           449)], (222-213')-disulfure avec la chaîne légère kappa (1'-213')
                           [Mus musculus V-KAPPA (IGKV4-55*01 -IGKJ1*01) [5.3.9] (1'-106')
                           -Homo sapiens IGKC*01 (107'-213')]; dimère (228-228'':231-231'')-
                           bisdisulfure

 siltuximab                inmunoglobulina G1-kappa, anti-[Homo sapiens interleukina 6 (IL6,
                           IL-6)], anticuerpo monoclonal quimérico;
                           cadena pesada gamma1 (1-449) [Mus musculus VH (IGHV5-9-4*01
                           -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-
                           449)], (222-213')-disulfuro con la cadena ligera kappa (1'-213') [Mus
                           musculus V-KAPPA (IGKV4-55*01 -IGKJ1*01) [5.3.9] (1'-106') -
                           Homo sapiens IGKC*01 (107'-213')]; dímero (228-228'':231-231'')-
                           bisdisulfuro

                           C6450H9932N1688O2016S50

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGK LLKPGGSLKL SCAASGFTFS                  SFAMSWFRQS       PEKRLEWVAE          50
                           ISSGGSYTYY PDTVTGRFTI SRDNAKNTLY                  LEMSSLRSED       TAMYYCARGL         100
                           WGYYALDYWG QGTSVTVSSA STKGPSVFPL                  APSSKSTSGG       TAALGCLVKD         150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSSLGTQTY         200
                           ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP                  CPAPELLGGP       SVFLFPPKPK         250
                           DTLMISRTPE VTCVVVDVSH EDPEVKFNWY                  VDGVEVHNAK       TKPREEQYNS         300
                           TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL                  PAPIEKTISK       AKGQPREPQV         350
                           YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA                  VEWESNGQPE       NNYKTTPPVL         400
                           DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM                  HEALHNHYTQ       KSLSLSPGK          449

                           Light chain / Chaîne légère / Cadena ligera
                           QIVLIQSPAI MSASPGEKVT MTCSASSSVS YMYWYQQKPG                        SSPRLLIYDT          50
                           SNLASGVPVR FSGSGSGTSY SLTISRMEAE DAATYYCQQW                        SGYPYTFGGG         100
                           TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP                        REAKVQWKVD         150
                           NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV                        YACEVTHQGL         200
                           SSPVTKSFNR GEC                                                                        213

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 146-202              263-323  369-427
                                    22''-96'' 146''-202'' 263''-323'' 369''-427''
                           Intra-L 23'-87'      133'-193'
                                    23'''-87''' 133'''-193'''
                           Inter-H-L 222-213' 222''-213'''
                           Inter-H-H 228-228'' 231-231''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           299, 299''


262
WHO Drug Information Vol 23, No. 3, 2009                                                    Recommended INN: List 62




 sobetiromum
 sobetirome                                (4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-
                                           3,5-dimethylphenoxy)acetic acid

 sobétirome                                acide (4-{[4-hydroxy-3-(1-méthyléthyl)phényl]méthyl}-
                                           3,5-diméthylphénoxy)acétique

 sobetiroma                                ácido (4-{[4-hidroxi-3-(propan-2-il)fenil]metil}-
                                           3,5-dimetilfenoxi)acético

                                           C20H24O4

                                                  HO           H3 C              O   CO2H

                                            H3C

                                                   CH3                     CH3



 sofiniclinum
 sofinicline                               (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane

 sofinicline                               (-)-(1S,5S)-3-(5,6-dichloropyridin-3-yl)-
                                           3,6-diazabicyclo[3.2.0]heptane

 sofiniclina                               (1S,5S)-3-(5,6-dicloropiridin-3-il)-3,6-diazabiciclo[3.2.0]heptano

                                           C10H11Cl2N3

                                                           N          Cl

                                           H
                                                       N              Cl

                                            N
                                            H     H



 solanezumabum #
 solanezumab                               immunoglobulin G1-kappa, anti-[Homo sapiens amyloid-beta (Abeta)
                                           peptide soluble monomer], humanized monoclonal antibody;
                                           gamma1 heavy chain [humanized VH (Homo sapiens IGHV3-23*04
                                           (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens
                                           IGHG1*01, CH3 K130>del (113-441)], (215-219')-disulfide with
                                           kappa light chain (1’-219’) [humanized V-KAPPA (Homo sapiens
                                           IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
                                           IGKC*01 (113'-219')]; (221-221":224-224")-bisdisulfide dimer

 solanezumab                               immunoglobuline G1-kappa, anti-[Homo sapiens amyloïde-bêta
                                           (Abeta) peptide monomère soluble], anticorps monoclonal humanisé;
                                           chaîne lourde gamma1 [VH humanisé (Homo sapiens IGHV3-23*04
                                           (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens
                                           IGHG1*01, CH3 K130>del (113-441)], (215-219')-disulfure avec la
                                           chaîne légère kappa (1’-219’) [V-KAPPA humanisé (Homo sapiens
                                           IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
                                           IGKC*01 (113'-219')]; dimère (221-221":224-224")-bisdisulfure




                                                                                                                 263
Recommended INN: List 62                                            WHO Drug Information Vol 23, No. 3, 2009


 solanezumab                    inmunoglobulina G1-kappa, anti-[péptido amiloide-beta (Abeta)
                                monomèrico soluble de Homo sapiens], anticuerpo monoclonal
                                humanizado;
                                cadena pesada gamma1 [VH humanizada (Homo sapiens IGHV3-
                                23*04 (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens
                                IGHG1*01, CH3 K130>del (113-441)], (215-219')-disulfuro con la
                                cadena ligera kappa (1’-219’) [V-KAPPA humanizada (Homo
                                sapiens IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo
                                sapiens IGKC*01 (113'-219')]; dímero (221-221":224-224")-
                                bisdisulfuro

                                C6396H9922N1712O1996S42

                                Heavy chain / Chaîne lourde / Cadena pesada
                                EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  RYSMSWVRQA       PGKGLELVAQ        50
                                INSVGNSTYY PDTVKGRFTI SRDNAKNTLY                  LQMNSLRAED       TAVYYCASGD       100
                                YWGQGTLVTV SSASTKGPSV FPLAPSSKST                  SGGTAALGCL       VKDYFPEPVT       150
                                VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV                  VTVPSSSLGT       QTYICNVNHK       200
                                PSNTKVDKKV EPKSCDKTHT CPPCPAPELL                  GGPSVFLFPP       KPKDTLMISR       250
                                TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH                  NAKTKPREEQ       YNSTYRVVSV       300
                                LTVLHQDWLN GKEYKCKVSN KALPAPIEKT                  ISKAKGQPRE       PQVYTLPPSR       350
                                DELTKNQVSL TCLVKGFYPS DIAVEWESNG                  QPENNYKTTP       PVLDSDGSFF       400
                                LYSKLTVDKS RWQQGNVFSC SVMHEALHNH                  YTQKSLSLSP       G                441

                                Light chain / Chaîne légère / Cadena ligera
                                DVVMTQSPLS LPVTLGQPAS ISCRSSQSLI                  YSDGNAYLHW       FLQKPGQSPR 50
                                LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCSQSTHVP 100
                                WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                VTHQGLSSPV TKSFNRGEC                                                          219

                                Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                Intra-H 22-96 139-195              256-316  362-420
                                         22''-96'' 139''-195'' 256''-316'' 362''-420''
                                Intra-L 23'-93'      139'-199'
                                         23'''-93''' 139'''-199'''
                                Inter-H-L 215-219' 215''-219'''
                                Inter-H-H 221-221'' 224-224''

                                N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                292, 292''



 taberminogenum vadenovecum #
 taberminogene vadenovec        recombinant E1a and E3 deleted (non-replicating), adenovirus
                                (serotype 5) containing a vascular endothelial growth factor – D
                                (VEGF-D) gene driven by a CMV promoter

 taberminogène vadénovec        adénovirus (sérotype 5) recombinant (non répliquant), régions E1a
                                et E3 supprimées, contenant un gène du facteur de croissance de
                                l'endothélium vasculaire – D (VEGF-D), sous contrôle d'un
                                promoteur de cytomégalovirus (CMV)

 taberminogén vadenovec         adenovirus recombinante (serotipo 5) (no replicativo) con deleción
                                de los genes E1a y E3, que contiene el factor de crecimiento
                                endotelial vascular – D (VEGF-D) bajo el control de un promotor de
                                citomegalovirus (CMV)



      tarafenacinum
      tarafenacin                 (3R)-1-azabicyclo[2.2.2]octan-3-yl (3-fluorophenyl)[(3,4,5-
                                  trifluorophenyl)methyl]carbamate

      tarafénacine                (3-fluorophényl)[(3,4,5-trifluorophényl)méthyl]carbamate de
                                  (3R)-1-azabicyclo[2.2.2]oct-3-yle

      tarafenacina                (3-fluorofenil)[(3,4,5-trifluorofenil)metil]carbamato de
                                  (3R)-1-azabiciclo[2.2.2]octan-3-ilo



264
WHO Drug Information Vol 23, No. 3, 2009                                                                   Recommended INN: List 62


                                            C21H20F4N2O2

                                                                  O
                                                                        H
                                             F                N         O
                                                                                         N
                                             F


                                             F
                                                      F



 telcagepantum
 telcagepant                               N-[(3R,6S)-6-(2,3-diflurophenyl)-2-oxo-1-(2,2,2-trifluroethyl)azepan-
                                           3-yl]-4-{2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl}piperidine-
                                           1-carboxamide

 telcagépant                               N-[(3R,6S)-6-(2,3-difluorophényl)-2-oxo-1-(2,2,2-trifluoroéthyl)-
                                           azépan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-
                                           1-yl)pipéridine-1-carboxamide

 telcagepant                               N-[(3R,6S)-6-(2,3-difluorofenil)-2-oxo-1-(2,2,2-trifluoroetil)azepan-
                                           3-il]-4-{2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-1-il}piperidina-
                                           1-carboxamida

                                           C26H27F5N6O3

                                                                                              O
                                                                                                      NH
                                                                  CF3
                                                                                                  N        N
                                                              N       O
                                                                       H
                                                  H                    N             N
                                                                        H
                                                                            O
                                                      F
                                              F



 tilivapramum
 tilivapram                                4-[4-(cyclopropylmethoxy)-5-methoxypyridine-2-carboxamido]-
                                           3,5-dichloropyridine 1-oxide

 tilivapram                                1-oxyde de 4-[4-(cyclopropylméthoxy)-5-méthoxypyridine-
                                           2-carboxamido]-3,5-dichloropyridine

 tilivapram                                1-óxido de 4-[4-(ciclopropilmetoxi)-5-metoxipiridina-2-carboxamido]-
                                           3,5-dicloropiridina

                                           C16H15Cl2N3O4

                                                  H3CO
                                                                    N                        Cl
                                                                                H
                                                                                N
                                                          O
                                                                            O                     N
                                                                                Cl                    O




                                                                                                                                265
Recommended INN: List 62                                       WHO Drug Information Vol 23, No. 3, 2009


 toceranibum
 toceranib                  5-[(5Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-
                            2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide

 tocéranib                  5-[(5Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidène)méthyl]-
                            2,4-diméthyl-N-[2-(pyrrolidin-1-yl)éthyl]-1H-pyrrole-3-carboxamide

 toceranib                  5-[(5Z)-(5-fluoro-2-oxo-1,2-dihidro-3H-indol-3-ilideno)metil]-
                            2,4-dimetil-N-[2-(pirrolidin-1-il)etil]-1H-pirrol-3-carboxamida

                            C22H25FN4O2

                                           H
                                           N
                                               O
                                                   H
                                                   N       CH3
                             F                                      H
                                                                    N
                                                                               N
                                               H3 C        O



 tozasertibum
 tozasertib                 N-[4-({4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-
                            3-yl)amino]pyrimidin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide

 tozasertib                 N-[4-({4-(4-méthylpipérazin-1-yl)-6-[(5-méthyl-1H-pyrazol-
                            3-yl)amino]pyrimidin-2-yl}sulfanyl)phényl]cyclopropanecarboxamide

 tozasertib                 N-[4-({4-(4-metilpiperazin-1-il)-6-[(5-metil-1H-pirazol-
                            3-il)amino]pirimidin-2-il}sulfanil)fenil]ciclopropanocarboxamida

                            C23H28N8OS

                                                                                       CH3
                                                                                   N
                                                       S        N        N
                                   O
                                                           N
                                       N
                                       H
                                                               HN
                                                                                   CH3
                                                                        N NH




 vanutidum cridificarum #
 vanutide cridificar        inactivated diphtheria toxin (carrier) covalently linked to human
                            beta-amyloid protein 42 short fragments:
                                            6-Lys
                            pentadecakis[N        -(sulfanylacetyl)]-[52-glutamic
                            acid(G>E)]diphtheria toxin Corynebacterium diphtheriae thioether
                            with human beta-amyloid protein 42-(1-7)-peptidylcysteine

 vanutide cridificar        court fragment de la protéine 42 bêta-amyloïde liée de façon
                            covalente à la toxine diphtérique inactivée (vecteur) :
                            thioéthers entre la protéine 42 bêta-amyloïde humaine-
                                                                       6-Lys
                            (1-7)peptidylcystéine et la pentadécakis[N       -(sulfanylacétyl)]-
                            [52-acide glutamique(G>E)]toxine diphtérique Corynebacterium
                            diphtheriae




266
WHO Drug Information Vol 23, No. 3, 2009                                                              Recommended INN: List 62




 vanutida cridificar                       pequeño fragmento de la proteína 42 beta-amiloide unido
                                           covalentemente a la toxina diftérica inactivada (vector) :
                                           tioéteres entre la proteína 42 beta-amiloide humana-
                                                                                     6-Lys
                                           (1-7)peptidilcisteína y la pentadecakis[N       -(sulfanilacetil)]-[52-ácido
                                           glutámico G>E)]toxina diftérica Corynebacterium diphtheriae

                                           C3215H4916N900O1053S27

                                             GADDVVDSSK      SFVMENFSSY       HGTKPGYVDS       IQKGIQKPKS       GTQGNYDDDW         50
                                             KEFYSTDNKY      DAAGYSVDNE       NPLSGKAGGV       VKVTYPGLTK       VLALKVDNAE         100
                                             TIKKELGLSL      TEPLMEQVGT       EEFIKRFGDG       ASRVVLSLPF       AEGSSSVEYI         150
                                             NNWEQAKALS      VELEINFETR       GKRGQDAMYE       YMAQACAGNR       VRRSVGSSLS         200
                                             CINLDWDVIR      DKTKTKIESL       KEHGPIKNKM       SESPNKTVSE       EKAKQYLEEF         250
                                             HQTALEHPEL      SELKTVTGTN       PVFAGANYAA       WAVNVAQVID       SETADNLEKT         300
                                             TAALSILPGI      GSVMGIADGA       VHHNTEEIVA       QSIALSSLMV       AQAIPLVGEL         350
                                             VDIGFAAYNF      VESIINLFQV       VHNSYNRPAY       SPGHKTQPFL       HDGYAVSWNT         400
                                             VEDSIIRTGF      QGESGHDIKI       TAENTPLPIA       GVLLPTIPGK       LDVNKSKTHI         450
                                             SVNGRKIRMR      CRAIDGDVTF       CRPKSPVYVG       NGVHANLHVA       FHRSSSEKIH         500
                                             SNEISSDSIG      VLGYQKTVDH       TKVNSKLSLF       FEIKS                               535

                                             Modified residues / Résidus modifiés / Residuos modificados
                                             K (-Lys-)                                                                         O
                                             an average of 15 out of 39 lysines are modified
                                             environ 15 des 39 lysines sont modifiées
                                             aproximadamente 15 de las 39 lisinas están modificadas
                                                                                                            H        S         NH

                                                      H Asp Ala Glu Phe Arg His Asp N                             CO2H
                                                                                    H

                                                                                                                          H

                                                                                                                         N       C
                                                                                                                         H
                                                                                                                                 O
                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            186-201 461-471




 vedolizumabum #
 vedolizumab                               immunoglobulin G1-kappa, anti-[Homo sapiens alpha4beta7 integrin
                                           (lymphocyte Peyer's patch adhesion molecule 1, LPAM-1),
                                           humanized monoclonal antibody;
                                           gamma1 heavy chain (1-451) [humanized VH (Homo sapiens
                                           IGHV1-3*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo
                                           sapiens IGHG1*01, CH2 L1.2>A, G1>A (122-451)], (224-219')-
                                           disulfide with kappa light chain (1'-219') [humanized V-KAPPA
                                           (Homo sapiens IGKV2-29*02 (84.00%) -IGKJ2*01, L124>V) [11.3.9]
                                           (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (230-230":233-233")-
                                           bisdisulfide dimer

 védolizumab                               immunoglobuline G1-kappa, anti-[Homo sapiens intégrine
                                           alpha4bêta7 (molécule 1 d'adhésion des lymphocytes des plaques
                                           de Peyer, LPAM-1), anticorps monoclonal humanisé;
                                           chaîne lourde gamma1 (1-451) [VH humanisé (Homo sapiens
                                           IGHV1-3*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo
                                           sapiens IGHG1*01, CH2 L1.2>A, G1>A (122-451)] , (224-219')-
                                           disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé
                                           (Homo sapiens IGKV2-29*02 (84.00%) -IGKJ2*01, L124>V) [11.3.9]
                                           (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (230-
                                           230":233-233")-bisdisulfure




                                                                                                                                         267
Recommended INN: List 62                                      WHO Drug Information Vol 23, No. 3, 2009


 vedolizumab               inmunoglobulina G1-kappa, anti-[ integrina alfa4beta7 de Homo
                           sapiens (conocida como: molécula 1 de adhesión de los linfocitos de
                           las placas de Peyer, LPAM-1), anticuerpo monoclonal humanizado;
                           cadena pesada gamma1 (1-451) [VH humanizado (Homo sapiens
                           IGHV1-3*01 (84.70%) -(IGHD)-IGHJ4*01) [8.8.14] (1-121) -Homo
                           sapiens IGHG1*01, CH2 L1.2>A, G1>A (122-451)] , (224-219')-
                           disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada
                           (Homo sapiens IGKV2-29*02 (84.00%) -IGKJ2*01, L124>V) [11.3.9]
                           (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (230-
                           230":233-233")-bisdisulfuro

                           C6528H10072N1732O2042S42

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKGSGYTFT                  SYWMHWVRQA       PGQRLEWIGE        50
                           IDPSESNTNY NQKFKGRVTL TVDISASTAY                  MELSSLRSED       TAVYYCARGG       100
                           YDGWDYAIDY WGQGTLVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                           TYICNVNHKP SNTKVDKKVE PKSCDKTHTC                  PPCPAPELAG       APSVFLFPPK       250
                           PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                           QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450
                           K                                                                                   451

                           Light chain / Chaîne légère / Cadena ligera
                           DVVMTQSPLS LPVTPGEPAS ISCRSSQSLA                  KSYGNTYLSW       YLQKPGQSPQ 50
                           LLIYGISNRF SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCLQGTHQP 100
                           YTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219


                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        148-204       265-325  371-429
                                     22''-96'' 148''-204'' 265''-325'' 371''-429''
                           Intra-L 23'-93' 139'-199'
                                    23'''-93''' 139'''-199'''
                           Inter-H-L 224-219' 224''-219'''
                           Inter-H-H 230-230'' 233-233''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           301, 301''




 zicronapinum
 zicronapine               4-[(1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl]-
                           1,2,2-trimethylpiperazine

 zicronapine               4-[(1R,3S)-6-chloro-3-phényl-2,3-dihydro-1H-indén-1-yl]-
                           1,2,2-triméthylpipérazine

 zicronapina               4-[(1R,3S)-6-cloro-3-fenil-2,3-dihidro-1H-inden-1-il]-
                           1,2,2-trimetilpiperazina

                           C22H27ClN2

                                                            CH3
                                                        N
                            Cl               H
                                                 N           CH3
                                                            CH3


                                         H




268
WHO Drug Information Vol 23, No. 3, 2009                                                       Recommended INN: List 62



                            AMENDMENTS TO PREVIOUS LISTS
                    MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                        MODIFICACIONES A LAS LISTAS ANTERIORES


Recommended International Non Proprietary Names (Rec. INN): List 53
Dénominations communes internationales recommandées (DCI Rec.): Liste 53
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 53
(WHO Drug Information, Vol. 19, No. 1, 2005)

p. 83     suprimáse                    insértese
          lenalidomide                 lenalidomida




Recommended International Non Proprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 21, No. 2, 2007)

p. 45     supprimer                    insérer
          bromure d'azixomère          bromure d'azoximère




Recommended International Non Proprietary Names (Rec. INN): List 61
Dénominations communes internationales recommandées (DCI Rec.): Liste 61
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61
(WHO Drug Information, Vol. 23, No. 1, 2009)



p. 52   bafetinibum
        bafetinib                      replace the chemical name and the structure by the following
        bafétinib                      remplacer le nom chimique et la structure par les suivants
        bafetinib                      sustitúyase el nombre químico y la fórmula desarrollada por los siguientes

                                       N-{3-[([4,5'-bipyrimidin]-2-yl)amino]-4-methylphenyl}-4-{[(3S)-3-
                                       (dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide

                                       N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-méthylphényl]-4-{[(3S)-3-
                                       (diméthylamino)pyrrolidin-1-yl]méthyl}-3-(trifluorométhyl)benzamide

                                       N-{3-[([4,5'-bipirimidin]-2-il)amino]-4-metilfenil}-4-{[(3S)-3-
                                       (dimetilamino)pirrolidin-1-il]metil}-3-(trifluorometil)benzamida

                                                                                                  N
                                                        N
                                                                       H           H
                                       H3 C                            N           N     N            N
                                              N         F3C
                                                    H
                                              CH3                  O                 N
                                                                                   CH3




                                                                                                                    269
 Recommended INN: List 62                                                     WHO Drug Information Vol 23, No. 3, 2009




 p. 66     levomilnacipranum
           levomilnacipran              replace the structure by the following
           lévomilnacipran              remplacer la structure par la suivante
           levomilnaciprán              sustitúyase la fórmula desarrollada por la siguiente

                                                       CH3

                                             O     N     CH3
                                                   H
                                                          NH2




 #   Electronic structure available on Mednet: http://mednet.who.int/
 #   Structure électronique disponible sur Mednet: http://mednet.who.int/
 #   Estructura electrónica disponible en Mednet: http://mednet.who.int/




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




 270
